Nabriva Therapeutics

FDA Building 2

Pharma

Sanofi hits pause on rare disease candidate after FDA rejection

Sanofi is pressing pause on a rare disease candidate after the FDA found issues at a contract manufacturer's plant.

Kyle Blankenship Nov 16, 2020 10:42am

fda

Nabriva hit with 2nd FDA complete response letter for Contepo

Jun 22, 2020 10:00am

Xenleta lefamulin

Nabriva scores its first FDA nod with novel antibiotic Xenleta

Aug 19, 2019 12:26pm